PEACHES DUON: Open Payments
NPI 1326622788 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,181 in 52 payments from 17 companies in 2025. Trend: 2023 $114 · 2024 $149 · 2025 $1,181
Food & beverage: $1,181
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $384 |
| Lilly USA, LLC | 4 | $145 |
| Otsuka America Pharmaceutical, Inc. | 4 | $100 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $97 |
| Amgen Inc. | 3 | $71 |
| AstraZeneca Pharmaceuticals LP | 4 | $61 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $46 |
| Novo Nordisk Inc | 2 | $39 |
| Exact Sciences Corporation | 2 | $37 |
Products named: CREON, VRAYLAR, REXULTI, ZEPBOUND, CAPLYTA, JARDIANCE, QULIPTA, LINZESS.
Industry payments across NV — which companies pay providers there.
